IRD
Opus Genetics, Inc. Healthcare Biotechnology
5/12
Innovation Score
Red Flags (1)
SBC_HIGH (679% of revenue)
Patent Activity
2/3
5 patents found
OK_NORMALIZED
Cash Runway
2/3
26 months of cash remaining based on current burn rate.
Cash on hand: $88.8M
Cash on hand: $88.8M
Revenue Trajectory
0/3
Revenue: $9.9M
YoY Growth: -73.8%
YoY Growth: -73.8%
Management Quality
1/3
Insider ownership: 21.6%
SBC/Revenue: 679.2%
No reverse splits detected
SBC/Revenue: 679.2%
No reverse splits detected
Key Metrics
Market Cap
$300.3M
Revenue
$9.9M
Revenue Growth (YoY)
-73.8%
Cash on Hand
$88.8M
Cash Runway
26 months
Shares Outstanding
83.2M
Insider Ownership
21.6%
SBC / Revenue
679.2%
Sector / Industry
Healthcare / Biotechnology
Patents (5)
Match type: OK_NORMALIZED
- Salts and esters of APX3330 and therapeutic uses thereof
- Methods and compositions for treatment of mydriasis
- Aqueous ophthalmic solutions of phentolamine and medical uses thereof
- Methods and compositions for treatment of mydriasis
- Methods and compositions for treatment of glaucoma and related conditions
7-Step Risk Assessment
How IRD maps to our micro cap methodology:
- Innovation Signal 5 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 26 months of runway. Comfortable buffer for execution.
- Revenue Trajectory -73.8% YoY growth on $9.9M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 21.6% of shares. SBC is 679.2% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $300.3M company.
Financial Detail
Free Cash Flow
$-38.6M
FCF Yield
-12.8%
Return on Equity
-4796.5%
Debt / Equity
N/A
Gross Margin
-291.9%
Profit Margin
N/A
Operating Margin
-2182.8%
Price / Book
-22.99
Current Ratio
12.19
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-08-15